The Treat-to-Target Trial and related studies.

Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
Matthew C Riddle

Abstract

To describe the rationale for, and the findings of, the Treat-to-Target Trial and to compare its results with those of two subsequent studies based on the same concepts. The 24-hour pattern of hyperglycemia in type 2 diabetes is presented, and its separate components are identified in an attempt to help optimize therapeutic interventions for diabetes. In addition, the treat-to-target concept, including glycemic outcomes and potential adverse effects, is discussed. Using a hemoglobin A1c (A1c) value of 7% as a treatment goal based on evidence from interventional studies and a fasting plasma glucose level of 100 mg/dL as a target for titration of dosage of basal insulin, the Treat-to-Target Trial tested two hypotheses. It confirmed that addition of basal insulin to previously unsuccessful oral therapies can, using a simple algorithm, restore glycemic control to 7% A1c or better in most patients with type 2 diabetes. It also confirmed that a long-acting insulin analogue, glargine, causes less hypoglycemia than human NPH insulin when used in this way. Two subsequent studies using similar treatment algorithms showed comparable ability to improve glycemic control but also demonstrated more frequent unwanted effects of insulin treatme...Continue Reading

References

Feb 26, 1977·Lancet·R R Holman, R C Turner
Jun 1, 1990·Diabetes Care·M C Riddle
Sep 12, 2000·Lancet·G B Bolli, D R Owens
Oct 4, 2002·The American Journal of Medicine·John E Gerich
Oct 28, 2003·Diabetes Care·Matthew C RiddleUNKNOWN Insulin Glargine 4002 Study Investigators
Nov 7, 2003·The Journal of Clinical Endocrinology and Metabolism·Mary F CarrollDavid S Schade
Dec 25, 2003·Diabetes·Mary Courtney MooreAlan D Cherrington
Jun 29, 2004·Diabetes Care·Jonathan B BrownAndrew Perry
Sep 10, 2004·The New England Journal of Medicine·Hannele Yki-Järvinen
Jan 29, 2005·Diabetes Care·Philip RaskinUNKNOWN INITIATE Study Group

❮ Previous
Next ❯

Citations

Apr 17, 2010·Primary Care Diabetes·Luigi MeneghiniMartin J Abrahamson
Feb 19, 2014·Nature Reviews. Endocrinology·Vivian A Fonseca, Michelle A Haggar
Aug 7, 2013·Endocrinología y nutrición : órgano de la Sociedad Española de Endocrinología y Nutrición·Pedro Mezquita-RayaUNKNOWN Diabetes Mellitus Working Group of the Spanish Society of Endocrinology and Nutrition (SEEN)
Aug 25, 2015·Comparative Biochemistry and Physiology. Toxicology & Pharmacology : CBP·Arumugam KamaladeviKrishnaswamy Balamurugan
Dec 18, 2012·Diabetes, Obesity & Metabolism·S C L GoughM Davies
Oct 15, 2013·Diabetes, Obesity & Metabolism·A J Garber
Apr 20, 2007·The Cochrane Database of Systematic Reviews·K HorvathA Siebenhofer
Jan 1, 2012·Expert Review of Endocrinology & Metabolism·Luigi F Meneghini, Bresta Miranda-Palma
Apr 1, 2017·Expert Opinion on Drug Delivery·Timothy S Bailey, Jenine Y Stone
Jul 1, 2014·Expert Review of Endocrinology & Metabolism·Victoria Stokes, Stephen Cl Gough

❮ Previous
Next ❯

Related Concepts

Related Feeds

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.